NZ335922A - Use of leukotriene antagonists for treating squamous cell carcinoma (cancer) - Google Patents
Use of leukotriene antagonists for treating squamous cell carcinoma (cancer)Info
- Publication number
- NZ335922A NZ335922A NZ335922A NZ33592297A NZ335922A NZ 335922 A NZ335922 A NZ 335922A NZ 335922 A NZ335922 A NZ 335922A NZ 33592297 A NZ33592297 A NZ 33592297A NZ 335922 A NZ335922 A NZ 335922A
- Authority
- NZ
- New Zealand
- Prior art keywords
- alkyl
- bond
- halo
- hydrogen
- independently
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed is the use of the above compound, having activity as a leukotriene B4 antagonist, for the treatment or inhibition of oral squamous cell carcinoma. Treatment involves administering to a mammal in need thereof an effective amount of a compound of the formula I wherein: R1 is C1-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl, C1-C4 alkoxy, (C1-C4 alkyl)thio, halo, or R2-substituted phenyl; R2 and R3 are each independently hydrogen, halo, hydroxy, C1-C4 alkyl, C1-C4 alkoxy, (C1-C4 alkyl)-S(O)q-, trifluoromethyl, or di-(C1-C3alkyl)amino; X is -O-, -S-, -C(=O), or -CH2-; Y is -O- or -CH2-, or when taken together, -X-Y- is -CH=CH- or -C=C-; Z is a straight or branched chain C1-C10 alkylidenyl; A is a bond, -0-, -S-, -CH=CH-, or -CRaRb-, where Ra and Rb are each independently hydrogen, C1-C5 alkyl, or R7-substituted phenyl, or when taken together with the carbon atom to which they are attached, form a C4-C8 cycloalkyl ring; R4 is R6, or figure Ia, Ib, Ic, Id, Ie or If' where, R6 is independently -COOH, 5-tetrazolyl, -CON(R9)2, or -CONHSO2Rl0; R7 is hydrogen, Cl-C4 alkyl, C2-Cs alkenyl, C2-C5 alkynyl, benzyl, methoxy, -W-R6, -T-G-R6, (C1-C4 alkyl)-T-(C1-C4 alkylidenyl)-O-, or hydroxy; R8 is hydrogen or halo; R9 is independently hydrogen, phenyl, or C1-C4 alkyl, or when taken together with the nitrogen atom form a morpholino, piperidino, piperazino, or pyrrolidino group; R10 is C1-C4 alkyl or phenyl; R11 is R2, -W-R6, or -T-G-R6; W is a bond or straight or branched chain divalent hydrocarbyl radical of one to eight carbon atoms; G is a straight or branched chain divalent hydrocarbyl radical of one to eight carbon atoms; T is a bond, -CH2-, -O-, -NH-, -NHCO-, -C(=O)-, or -S(O)q"-; K is -C(=O)- or -CH(OH)-; q is independently 0, 1, or 2; p is 0 or 1; t is 0 or 1; provided when X is -O- or -S-, Y is not -O-; provided when A is -O- or -S-, R4 is not R6; provided when A is -O- or -S- and Z is a bond, Y is not -0-; provided W is not a bond when p is 0;
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3426996P | 1996-12-13 | 1996-12-13 | |
US4087497P | 1997-03-21 | 1997-03-21 | |
PCT/US1997/021953 WO1998025615A1 (en) | 1996-12-13 | 1997-12-02 | Leukotriene antagonists for oral squamous cell carcinoma |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ335922A true NZ335922A (en) | 2000-12-22 |
Family
ID=26710754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ335922A NZ335922A (en) | 1996-12-13 | 1997-12-02 | Use of leukotriene antagonists for treating squamous cell carcinoma (cancer) |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0964683A4 (en) |
JP (1) | JP2001509142A (en) |
KR (1) | KR20000069452A (en) |
CN (1) | CN1245429A (en) |
AU (1) | AU726215B2 (en) |
CA (1) | CA2274855A1 (en) |
EA (1) | EA002742B1 (en) |
IL (1) | IL130304A0 (en) |
NO (1) | NO992846L (en) |
NZ (1) | NZ335922A (en) |
PL (1) | PL334241A1 (en) |
TR (1) | TR199901307T2 (en) |
UA (1) | UA47505C2 (en) |
WO (1) | WO1998025615A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002009700A1 (en) | 2000-07-28 | 2002-02-07 | Cancer Research Technology Limited | Cancer treatment by combination therapy |
GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
GB2386836B (en) | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
GB2394658A (en) | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
US8093253B2 (en) * | 2008-03-06 | 2012-01-10 | Hoffmann-La Roche Inc. | Leukotriene B4 inhibitors |
KR101898879B1 (en) | 2014-03-05 | 2018-09-14 | 재단법인 진안홍삼연구소 | A composition comprising the red ginseng extract of postmanufacture for treating or preventing oral squamous cell carcinoma |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6372648A (en) * | 1986-09-16 | 1988-04-02 | Sumitomo Pharmaceut Co Ltd | Novel unsaturated fatty acid derivative |
CZ276694A3 (en) * | 1991-11-25 | 1995-11-15 | Lilly Co Eli | Process for preparing diphenyl derivative |
PH30449A (en) * | 1991-11-25 | 1997-05-28 | Lilly Co Eli | Substituted phenyl phenol leukotriene antagonists |
-
1997
- 1997-02-12 UA UA99063226A patent/UA47505C2/en unknown
- 1997-12-02 CA CA002274855A patent/CA2274855A1/en not_active Abandoned
- 1997-12-02 JP JP52676298A patent/JP2001509142A/en not_active Ceased
- 1997-12-02 IL IL13030497A patent/IL130304A0/en unknown
- 1997-12-02 EA EA199900543A patent/EA002742B1/en not_active IP Right Cessation
- 1997-12-02 TR TR1999/01307T patent/TR199901307T2/en unknown
- 1997-12-02 WO PCT/US1997/021953 patent/WO1998025615A1/en not_active Application Discontinuation
- 1997-12-02 EP EP97949709A patent/EP0964683A4/en not_active Withdrawn
- 1997-12-02 KR KR1019997005275A patent/KR20000069452A/en not_active Application Discontinuation
- 1997-12-02 AU AU78451/98A patent/AU726215B2/en not_active Ceased
- 1997-12-02 PL PL97334241A patent/PL334241A1/en unknown
- 1997-12-02 CN CN97181730A patent/CN1245429A/en active Pending
- 1997-12-02 NZ NZ335922A patent/NZ335922A/en unknown
-
1999
- 1999-06-11 NO NO992846A patent/NO992846L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU7845198A (en) | 1998-07-03 |
UA47505C2 (en) | 2002-07-15 |
EA002742B1 (en) | 2002-08-29 |
KR20000069452A (en) | 2000-11-25 |
EP0964683A4 (en) | 2002-08-14 |
WO1998025615A1 (en) | 1998-06-18 |
IL130304A0 (en) | 2000-06-01 |
AU726215B2 (en) | 2000-11-02 |
NO992846D0 (en) | 1999-06-11 |
CA2274855A1 (en) | 1998-06-18 |
NO992846L (en) | 1999-06-11 |
CN1245429A (en) | 2000-02-23 |
EA199900543A1 (en) | 2000-02-28 |
TR199901307T2 (en) | 1999-08-23 |
PL334241A1 (en) | 2000-02-14 |
JP2001509142A (en) | 2001-07-10 |
EP0964683A1 (en) | 1999-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA948026B (en) | Methods for inhibiting smooth muscle cell proliferation and restinosis | |
GEP20053688B (en) | Substituted-Triazolopyrimidines as Anticancer Agents | |
DE69923849D1 (en) | QUINOLIN-2-ON DERIVATIVES USE AS ANTICROPHOSIS | |
CA2280850A1 (en) | Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies | |
ES8404990A1 (en) | Anti-hypertensive prolinol-based peptides. | |
HUP0103386A2 (en) | Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect | |
MY112973A (en) | Methods for inhibiting vascular smooth muscle cell migration | |
NZ333315A (en) | Dipyridoxyl chelating agents and their metal chelates for treating free radicals induced conditions | |
DE69132713D1 (en) | Benzylidenthiazolidine derivatives, their preparation and their use as lipid peroxide inhibitors | |
NZ335922A (en) | Use of leukotriene antagonists for treating squamous cell carcinoma (cancer) | |
NZ514542A (en) | Vasopressin antagonists for the treatment of pulmonary hypertension | |
IL110831A0 (en) | Quinazolinone-containing pharmaceutical compositions and methods for the use thereof | |
MY121623A (en) | Methods of preventing breast cancer. | |
NZ511559A (en) | Use of staurosporine derivatives for treating ocular neovascular diseases | |
PT986393E (en) | USING A NITROXIDE OR ITS PRO-PHARMACY IN THE CANCER'S PROFILACTIC AND THERAPEUTIC TREATMENT | |
IL114951A0 (en) | Quinozolinone-containing pharmaceutical compositions for prevention of neovascularization | |
Edmonson et al. | Phase II Study of Recombinant Alfa-2a Interferon in Patients With Advanced Bone | |
NZ332348A (en) | use of triphenylethylene derivatives as antioxidant agents | |
NZ332687A (en) | use of 1-methyl-carbapenem derivatives as anti-helicobacter pylori agents | |
NZ337048A (en) | Use of N-[1-methyl-(substituted phenyl)ethyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide derivatives to treat prostate cancer | |
NZ333587A (en) | Topiramate derivatives useful in treating psoriasis | |
ES8707939A1 (en) | N-carboxyalcoyl-2-oxo-3-diaryl-5,6-triazines useful as therapeutic agents. | |
MXPA02001104A (en) | NEW CYTOTOXIC PYRIDO[2,3,4kl]ACRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE. | |
PL324086A1 (en) | Antagonists of calcium passages | |
Salomaa et al. | Ifosfamide combined with toremifene in the treatment of non-small cell lung cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) |